Bluejay Diagnostics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $249,040 | — |
| Cost of revenue | — | — | — | $200,129 | — |
| Gross profit | — | — | — | $48,911 | — |
| Selling, general & administrative | — | — | $283,443 | $451,421 | — |
| Research and development | $3.0M | $3.5M | $5.7M | $4.2M | $1.1M |
| Operating expenses | $7.0M | $7.2M | $10.3M | $9.4M | $3.2M |
| Operating income | -$7.0M | -$7.2M | -$10.3M | -$9.3M | -$3.2M |
| Interest expense | $839 | $823,028 | — | — | $6,360 |
| Net income | -$6.8M | -$7.7M | -$10.0M | -$9.3M | -$3.5M |
| Balance Sheet | |||||
| Cash and equivalents | $5.2M | $4.3M | $2.2M | $10.1M | $19.0M |
| Current assets | $5.5M | $4.9M | $3.2M | $11.8M | $20.7M |
| Total assets | $7.1M | $6.7M | $4.9M | $13.5M | $21.0M |
| Current liabilities | $1.1M | $810,368 | $1.8M | $1.6M | $637,162 |
| Total liabilities | $1.1M | $927,924 | $2.0M | $2.0M | $637,162 |
| Stockholders' equity | $6.0M | $5.7M | $2.9M | $11.5M | $20.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$6.1M | -$7.8M | -$8.3M | -$7.7M | -$4.4M |
| Depreciation and amortization | $74,182 | $75,618 | $648,708 | $156,598 | $145,719 |
| Stock-based compensation | $6 | $20,094 | $189,245 | $433,004 | $68,458 |
| Capital expenditure | $173,735 | $306,783 | $704,166 | $1.2M | $23,947 |
| Free cash flow | -$6.2M | -$8.1M | -$9.0M | -$8.9M | -$4.4M |
| Impairments | $42,937 | $3,411 | $1,787 | $237,309 | — |
Shares outstanding 1.0M · Free float 85.0%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.